The Science of Psychedelic Therapy
Explore peer-reviewed research supporting the therapeutic applications of psychedelic compounds. Our curriculum is grounded in evidence-based practice.
Study list last human-verified against PubMed on September 2, 2026
5-MeO-DMT (Bufo Alvarius)
6 peer-reviewed studies
5-MeO-DMT explained
- What it is
- 5-MeO-DMT is a fast-acting tryptamine found naturally in the Sonoran Desert toad and several plants. It produces the shortest, most intense experience of the classical psychedelics — typically under 30 minutes when vaporized. Clinically it is the most researched as an antidepressant; in 2026 a randomized trial reported remission in over half of treatment-resistant depression patients within eight days of a single-day dosing protocol.
- How it works
- Unlike classical psychedelics that act mainly on the serotonin 2A receptor, 5-MeO-DMT binds most strongly to the serotonin 1A receptor. That difference is why its effects feel qualitatively different: rapid onset, brief duration, and a high rate of complete ego dissolution, per peer-reviewed pharmacology reviews.
- Where the evidence stands
- Evidence is early but accelerating. A phase 2b randomized controlled trial published in JAMA Psychiatry in 2026 reported 57.5% remission at day 8 versus 0% on placebo in treatment-resistant depression. Systematic reviews report low adverse-event rates in supportive settings, and 2024 field research documents naturalistic use patterns. The evidence base is not yet at psilocybin or ketamine maturity, which is why structured facilitation and screening matter.
- Key cautions
- The intensity profile is the main risk factor: reviews describe a distinct risk profile tied to dosing, setting, and cardiovascular screening. Trauma-informed preparation and integration correlate with better outcomes. Legal status varies by jurisdiction; facilitation outside approved research contexts carries legal and professional risk.
- Recent developments
- 2025-2026: JAMA Psychiatry published the first large randomized trial of inhaled 5-MeO-DMT (GH001) for treatment-resistant depression; Psychopharmacology published a comprehensive pharmacology and risk review.
GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial
Cubala, W.J. et al. • JAMA Psychiatry • View on PubMed
Phase 2b randomized controlled trial: a single-day inhaled mebufotenin (5-MeO-DMT) protocol produced 57.5% remission at day 8 versus 0% on placebo in treatment-resistant depression.
5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?
Dourron, H.M. et al. • Psychopharmacology • View on PubMed
Comprehensive review: 5-MeO-DMT's 5-HT1A-dominant pharmacology, ultra-short duration, and intensity profile distinguish it from classical psychedelics, with distinct safety and screening considerations.
Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT): a systematic review
Kwaśny, A. et al. • Frontiers in Psychiatry • View on PubMed
Systematic review of safety data: adverse events are typically mild and transient in screened settings; screening and dose control drive risk.
A narrative synthesis of research with 5-MeO-DMT
Ermakova, A.O. et al. • Journal of Psychopharmacology • View on PubMed
Synthesis of the 5-MeO-DMT literature: intense experience profile, use patterns, and the research gaps that structured facilitation must address.
Reactivations Associated with the Use of 5-MeO-DMT Among Spanish-Speaking Individuals: Prevalence and Characteristics
Ortiz Bernal, A.M. et al. • Journal of Psychoactive Drugs • View on PubMed
Field study of post-experience reactivations: their prevalence, triggers, and management inform preparation protocols for safe practice.
Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy participants
Ermakova, A.O. et al. • Scientific Reports • View on PubMed
Controlled phenomenology study mapping the 5-MeO-DMT experience profile, informing how facilitators prepare and support participants.
Ketamine-Assisted Therapy
6 peer-reviewed studies
Ketamine explained
- What it is
- Ketamine is an approved anesthetic whose rapid antidepressant effect has made it the most clinically established psychedelic-assisted treatment. It is legally prescribable off-label for treatment-resistant depression, and its derivative esketamine carries FDA approval. It is the only one of the four compounds here that clinicians can incorporate into licensed practice today.
- How it works
- Ketamine blocks NMDA receptors, which triggers a glutamate surge and downstream AMPA activation — a mechanism distinct from SSRIs. This drives the rapid but time-limited antidepressant effect, which is why psychotherapy integration around each dosing session is central to durable outcomes.
- Where the evidence stands
- The evidence base is the deepest in the field: multiple randomized trials and meta-analyses report 60-70% response rates in treatment-resistant depression, a 2024 Nature Medicine trial showed significant PTSD reduction with ketamine-assisted psychotherapy at six months, and a 2025 systematic review compared IV ketamine against esketamine head-to-head.
- Key cautions
- Dissociation and blood-pressure elevation during dosing require medical screening and monitoring. Effects fade without repetition or psychotherapy, so treatment design matters more than the drug alone. Abuse liability calls for careful patient selection.
- Recent developments
- 2025: a systematic review and meta-analysis directly compared IV ketamine with esketamine for depression, sharpening route-of-administration decisions.
Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine: a randomized, placebo-controlled, phase 2 dose-finding trial
MacConnel, H.A. et al. • Journal of Psychopharmacology • View on PubMed
Randomized phase 2 trial: IV ketamine produced rapid, sustained reductions in treatment-resistant PTSD symptoms versus placebo.
Intravenous ketamine versus esketamine for depression: a systematic review and meta-analysis
Elmosalamy, A. et al. • Therapeutic Advances in Psychopharmacology • View on PubMed
Head-to-head meta-analysis comparing IV ketamine with esketamine across efficacy and safety, informing route-of-administration choices in clinical practice.
Ketamine combined with psychotherapy for treatment-resistant depression: Real-world evidence
Cohen, R. et al. • General Hospital Psychiatry • View on PubMed
Real-world data on ketamine paired with psychotherapy in treatment-resistant depression — the combination model this training teaches.
Distinct therapeutic profiles of ketamine in treatment-resistant depression: a systematic review
Liu, K.I. et al. • International Journal of Neuropsychopharmacology • View on PubMed
Systematic review separating ketamine's rapid antidepressant profile from its longer-term therapeutic pattern in treatment-resistant depression.
Dose-dependent adverse events of esketamine in treatment-resistant depression
Qu, Y. et al. • Frontiers in Pharmacology • View on PubMed
Adverse-event analysis across esketamine doses: medical monitoring thresholds for route and dose selection in clinical practice.
Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression
Hieronymus, F. et al. • JAMA Network Open • View on PubMed
Meta-analysis of control-group effects in psychedelic and antidepressant trials — context for how much of the response is compound versus care context.
Psilocybin-Assisted Therapy
6 peer-reviewed studies
Psilocybin explained
- What it is
- Psilocybin is the active compound in so-called magic mushrooms. After ingestion it converts to psilocin and produces a 4-6 hour experience. It is the most-studied psychedelic in psychiatry, with late-stage trials in treatment-resistant depression underway and no approval yet outside research settings.
- How it works
- Psilocin, the active metabolite, stimulates serotonin 2A receptors, which temporarily loosens the brain's default mode network — the network tied to rigid self-focus in depression. The subjective experience appears to open a window during which psychotherapy can rework entrenched patterns.
- Where the evidence stands
- Randomized trials show rapid, sustained antidepressant effects in major depression, positive results for alcohol use disorder and cancer-related existential distress, and — in 2025 — a 52-week follow-up study in the Journal of Clinical Psychiatry reported that a single 25 mg dose held longer-term antidepressant effects in treatment-resistant depression. A first phase 3 program reported positive topline results in 2025.
- Key cautions
- Psychological screening is essential: personal or family psychosis and bipolar history are standard exclusions. Sessions require hours of supervised support, and adverse events cluster around unsupervised or recreational settings rather than supervised ones.
- Recent developments
- 2025: 52-week follow-up of the 25 mg single-dose protocol published in the Journal of Clinical Psychiatry; the first phase 3 program in treatment-resistant depression hit its primary endpoint.
Long-term Follow-up Study of a Single Dose of Synthetic Psilocybin in Treatment-Resistant Depression (COMP004)
Goodwin, G.M. et al. • Journal of Clinical Psychiatry • View on PubMed
52-week observational follow-up: a single 25 mg COMP360 psilocybin dose showed longer-term antidepressant effects than lower doses, with response durability across a year.
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial
Raison, C.L. et al. • JAMA • View on PubMed
Landmark randomized trial in JAMA: a single 25 mg psilocybin session with psychotherapy produced rapid, sustained antidepressant effects.
Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial
Rosenblat, J.D. et al. • Med • View on PubMed
Independent randomized trial replicating single-dose psilocybin efficacy in treatment-resistant depression — evidence beyond the originating group.
Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
Agin-Liebes, G.I. et al. • Journal of Psychopharmacology • View on PubMed
Follow-up data: anxiety and depression reductions after psilocybin-assisted psychotherapy persisted at long-term follow-up in patients with life-threatening cancer.
Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin
Lebedev, A.V. et al. • Human Brain Mapping • View on PubMed
Neuroimaging study linking psilocybin-induced ego dissolution to disorganized activity in association networks — the mechanistic basis of the experience.
Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review
Bukovsky, D. et al. • Progress in Neuro-Psychopharmacology & Biological Psychiatry • View on PubMed
Systematic review of adverse-event handling across psilocybin trials: what safe protocols screen for and how they manage events.
MDMA-Assisted Therapy
4 peer-reviewed studies
MDMA explained
- What it is
- MDMA is an entactogen: it increases serotonin, oxytocin, and norepinephrine release, which reduces fear and increases trust during therapy sessions. It is not a classic psychedelic; its clinical value lies in making trauma processing tolerable. It remains an investigational compound — the FDA declined approval in 2024 and requested an additional trial.
- How it works
- By flooding the brain with serotonin and oxytocin while dampening the amygdala's fear response, MDMA creates a window of emotional openness. Within a structured therapy protocol, patients revisit traumatic memories without the usual flooding, which lets reconsolidation-based processing work.
- Where the evidence stands
- Two phase 3 trials (MAPP1, 2021; MAPP2, 2023, in Nature Medicine) showed significant PTSD symptom reduction with MDMA-assisted therapy, with benefits sustained in long-term follow-up. The FDA's 2024 complete response letter cited safety and data-quality concerns and requested an additional trial; approval remains pending, not rejected outright.
- Key cautions
- Cardiovascular screening is mandatory — MDMA raises heart rate and blood pressure. Because the compound increases trust and reduces threat perception, protocol integrity and screened therapist pairs matter; this is the area the FDA scrutinized.
- Recent developments
- 2024-2025: the FDA issued a complete response letter requesting an additional trial; the field is regrouping around protocol and data-quality improvements.
MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial
Mitchell, J.M. et al. • Nature Medicine • View on PubMed
Pivotal phase 3 trial (MAPP2): MDMA-assisted therapy significantly reduced PTSD symptoms, with 67% no longer meeting PTSD criteria at endpoint.
Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: a systematic review and meta-analysis
Fares-Otero, N.E. et al. • European Neuropsychopharmacology • View on PubMed
Meta-analysis pooling the MDMA-assisted therapy trials for PTSD: effect sizes, responder rates, and the safety picture across phase 2-3 studies.
Psychedelics: A review of their effects on recalled aversive memories and fear extinction
Werle, I. et al. • Neuroscience & Biobehavioral Reviews • View on PubMed
Review of how psychedelics including MDMA affect aversive memory reconsolidation and fear extinction — the mechanism behind MDMA-assisted trauma therapy.
Subjective and neurocognitive profiling of clinical doses of 3,4-methylenedioxymethamphetamine (MDMA)
Ramaekers, J.G. et al. • Molecular Psychiatry • View on PubMed
Controlled profiling of clinical MDMA doses: subjective and cognitive effects that define the therapeutic window.
Train in the Evidence-Based Approach
Our training programs integrate the latest research into practical therapeutic skills.